{"schema_version":"1","generated_at":"2026-10-31T02:32:15.331Z","data_as_of":null,"url":"https://www.findmykol.com/kol/jennifer-gile","json_url":"https://www.findmykol.com/kol/jennifer-gile/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"jennifer-gile","name":"Jennifer Gile","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"city":"Rochester","state":"MN","region":{"label":"Midwest","url":"https://www.findmykol.com/region/midwest"}},"identifiers":{"npi":"1336609288","orcid":"0000-0001-6972-7986","openalex":"A5063451759"},"summary":"Jennifer Gile is an Oncology physician. OpenAlex indexes 66 publications with 592 citations (h-index 12).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":66,"cited_by_count":592,"h_index":12,"latest_activity_year":2025,"source":"works"},"payments":{"company_count":2,"program_years":{"first":2021,"last":null},"rows_total":2,"shown":2,"withheld":0,"rows":[{"payer":"Secura Bio, Inc.","program_year":2025,"amount_usd":21.6,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1336609288"},{"payer":"Merck Sharp & Dohme Corporation","program_year":2021,"amount_usd":1000,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1336609288"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1336609288","source":"payments"},"prescribing":{"data_year":2024,"areas_total":4,"areas_shown":3,"areas":[{"area":"Metabolism & gastrointestinal","share_pct":34.8,"classes_total":1,"classes":[{"class":"Serotonin-3 Receptor Antagonist","setting":"prescribed","share_pct":34.8,"drugs":[{"name":"Ondansetron Hcl","share_pct":52.2},{"name":"Ondansetron Odt","share_pct":47.8}],"max_beneficiaries":null}]},{"area":"Sensory organs","share_pct":31.8,"classes_total":1,"classes":[{"class":"Corticosteroid","setting":"prescribed","share_pct":31.8,"drugs":[{"name":"Dexamethasone","share_pct":100}],"max_beneficiaries":null}]},{"area":"Dermatology","share_pct":16.7,"classes_total":1,"classes":[{"class":"Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor","setting":"prescribed","share_pct":16.7,"drugs":[{"name":"Acyclovir","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"office","data_year":2024,"office_pct":100,"facility_pct":0},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"First-line atezolizumab/bevacizumab or durvalumab/tremelimumab in advanced hepatocellular carcinoma: a real world, multicenter retrospective study","year":2025,"journal":"The Oncologist","source_url":"https://doi.org/10.1093/oncolo/oyaf286","status":"verified"},{"title":"Hypomagnesemia in lymphoma patients receiving CAR T therapy correlates with immune dysfunction and decreased survival","year":2025,"journal":"Experimental Hematology and Oncology","source_url":"https://doi.org/10.1186/s40164-025-00623-w","status":"verified"},{"title":"Atezolizumab plus bevacizumab as first-line systemic therapy for hepatocellular carcinoma: a multi-institutional cohort study","year":2024,"journal":"The Oncologist","source_url":"https://doi.org/10.1093/oncolo/oyae142","status":"verified"},{"title":"Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab","year":2024,"journal":"JHEP Reports","source_url":"https://doi.org/10.1016/j.jhepr.2024.101295","status":"verified"},{"title":"Second-line therapies in advanced hepatocellular carcinoma following first-line atezolizumab and bevacizumab: multicenter single institution cohort experience","year":2024,"journal":"The Oncologist","source_url":"https://doi.org/10.1093/oncolo/oyae342","status":"verified"}],"source":"works"},"contact":{"address_1":"200 1ST ST SW","city":"Rochester","state":"MN","zip":"559050002","phone":"507-284-2511","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1336609288","source":"identity"},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2022-06-30","provider_certified":"2022-06-30","collected_at":"2026-10-31T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}